Despite the evident promise of targeting splice factor kinases, Wang et al. emphasize an important caveat that applies to many other cancer-associated proteins—namely, that SRPK1 can potentially act as both an oncogene or tumour suppressor depending on the context. Here, SRPK1 is linked to neoplasm.